Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Goldman Sachs Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Goldman Sachs Group Inc trades at $1,060.5 (market cap $311.29B). The key difference: Goldman Sachs Group Inc is far larger — about 7.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Goldman Sachs Group Inc pays a 1.71% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GS | |
|---|---|---|
Market Cap | $39.89B | $311.29B |
Sector | Health | Financials |
52-Week High | $491.22 | $1.11K |
52-Week Low | $278.09 | $700.41 |
Enterprise Value | $38.15B | — |
Volume | — | 2,592,735 |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Goldman Sachs (GS) trades at $1,055.18, down 0.07% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $17.55 surpassing expectations of $16.47. Revenue grew to $58.28 billion in 2025, and net income margin improved to 29.89%. Recent news highlights GS's role in leading high-profile IPOs like Anthropic, signaling robust investment banking activity. The stock is near its pivot point of $1,055, with support at $1,045 and resistance at $1,065.
The outlook for GS is positive, driven by earnings momentum and a favorable IPO pipeline, but risks include volatile cash flows and macroeconomic sensitivity. Analyst consensus is a Buy with a price target of $1,080, indicating potential upside. Investors should monitor execution in investment banking and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
